Record-Setting Dark Matter Detector Comes Up Empty—and That's Good News
In a recent Physical Review Letters paper, scientists analyzed 280 days' worth of data from LUX-ZEPLIN, reporting the tightest ever upper limit on WIMPs. The result—a near fivefold improvement—demonstrates how physicists are increasingly getting better at circumventing the problem that dark matter is, well, dark; the elusive stuff evades any detection method that depends on materials interacting with visible light or other types of radiation.
There's ample evidence to suggest that dark matter does in fact exist, including numerous astrophysical observations hinting at some invisible matter exerting gravitational force on objects we can see. Physicists, as a result, tend to use materials that we can see, such as liquid forms of heavyweight elements like xenon, and simply wait for some unknown particle to interact with it. That strategy—waiting for particles to interact with heavy elements—is a well-tested approach for detecting WIMPs, hypothetical particles that interact with gravity but on a scale so tiny that only the most sensitive detectors might catch a glimpse.
The LUX-ZEPLIN experiment, located one mile underground in a decommissioned South Dakota gold mine, employs nearly 15,000 pounds (7 tons) of liquid xenon. The chemical element's high atomic mass and density make it potentially easier for scientists to detect any unknown particles that may pass through the detector. Also, liquid xenon is transparent, preventing any unwanted noise—usually arising from radioactive matter around the detector—from spoiling an experiment.
'If you think of the search for dark matter like looking for buried treasure, we've dug almost five times deeper than anyone else has in the past,' said Scott Kravitz, a physicist at the University of Texas at Austin and deputy coordinator for LZ, in a press release. 'That's something you don't do with a million shovels—you do it by inventing a new tool.'
The latest experiment also represents the first time the LZ team applied a technique called 'salting,' in which false WIMP signals were added in advance. This helped the researchers—who, of course, would love to find dark matter—avoid bias and stay skeptical of potentially promising signals.
'There's a human tendency to want to see patterns in data, so it's really important when you enter this new regime that no bias wanders in,' said Scott Haselschwart, a physicist at the University of Michigan and LZ physics coordinator, in the same release. 'If you make a discovery, you want to get it right.'
The next steps for the LZ experiment are to continue pressing against the upper limit for WIMPs and utilize the detector's cutting-edge technology to probe other interesting and rare physics processes, explained Amy Cottle, a physicist at University College London also involved with LZ, in the statement.
'We've demonstrated how strong we are as a WIMP search machine, and we're going to keep running and getting even better—but there's lots of other things we can do with this detector,' she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scientific American
3 hours ago
- Scientific American
Deep-Sea Desalination Pulls Drinking Water from the Depths
From Cape Town to Tehran to Lima to Phoenix, dozens of cities across the globe have experienced water shortages recently. And in the next five years the world's demand for fresh water could significantly outpace supply, according to a United Nations forecast. Now several companies are turning to an unexpected source for a solution: the bottom of the ocean. Called subsea desalination, the idea is to remove the salt from water in the deep sea. If it worked at scale, the technology could greatly alleviate the world's water access problems. Costs and energy requirements have kept desalination from going mainstream in most of the world. Early desalination involved boiling seawater and condensing the steam, a purely thermal method that used loads of energy. This approach was later replaced by multistage flash distillation, in which temperature and pressure 'flash' salt water to steam. In the past 25 years reverse osmosis has become more common—it uses high pressure to push seawater through a membrane with holes so small that only water molecules squeeze through, leaving salt behind. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. Reverse osmosis is more efficient than distillation, but it takes a lot of energy to pressurize millions of gallons of seawater and move it through filters. What if we could let that movement happen naturally by harnessing the pressure hundreds of meters underwater? That's the idea behind subsea desalination. Reverse osmosis pods are submerged to depths of around 500 meters (1,600 feet), where immense hydrostatic pressure does the heavy lifting of separating water from salt. Purified water is then pumped back to shore. Far-fetched as it may sound, there are multiple prototypes already at work; the companies behind them aim to take cheap, large-scale desalination from pipe dream to reality. One of these companies is Oslo-based Flocean. Its founder and CEO, Alexander Fuglesang, says there's no revolutionary new technology behind his business; it's 'essentially a subsea pump cleverly coupled to existing membrane and filter technology,' he says. What's new is the energy savings—Flocean uses 40 to 50 percent less energy than conventional plants—and modular systems that can be deployed to many deep-sea location without bespoke engineering. The seafloor has other benefits, too. This region harbors fewer bacteria and other microorganisms than at shallower depths, and there is little local variation in temperature or pressure. 'The deep sea is really predictable,' Fuglesang says. 'It's the same 365 days a year.' This isn't the case at land-based plants, which have to deal with algae blooms, river runoff, storms and seasonal temperature changes. Plus, less chemical pretreatment of the water is needed at depth, and because the equipment is all underwater, there's no 'not in my backyard' controversy over putting big, unsightly infrastructure near the seashore. Despite its advantages over land-based plants, subsea desalination has several hurdles to clear before scaling to commercial levels. For starters, it's still too expensive. Land-based desalination is several times more costly than pulling water from aquifers or lakes, even at giga-plants in the Middle East that benefit from abundant solar power and large economies of scale. Even if subsea technology cuts the cost of land-based desalination down by 40 percent, it will still be a pricey way to obtain potable water. 'We need to remember that once the water is desalinated, it still needs to be pumped up from depths of up to 600 meters,' says Nidal Hilal, founding director of New York University's Water Research Center in Abu Dhabi, who has studied water-treatment engineering for more than 30 years. 'Early pilot tests show promise, but the technology has yet to be proven at large scale.' Affordable renewable energy will make subsea desalination more viable. Improvements in technology will also help. Hilal's research group, for example, is developing electrically conductive reverse osmosis membranes that keep themselves clean by repelling salt ions and impurities. They would extend maintenance intervals, which Fuglesang says might be two to three years with existing membranes. Although proponents of the technology say it would have little effect on undersea life, others urge further research to gauge its impact on marine ecosystems. 'Many organisms thrive at a 500-meter depth,' says Adina Paytan, a professor affiliated with the Institute of Marine Sciences at the University of California, Santa Cruz. The twilight zone—which extends from 200 to 1,000 meters below the surface—is not only home to organisms such as whales, squid and jellyfish. 'It's extremely important for many ocean processes such as the carbon cycle and nutrient cycling,' Paytan says. Companies will need to ensure that their water intake and salty brine by-product don't harm marine life or significantly alter these processes. Given the depths required, subsea desalination won't work in just any seaside location. 'Many coastal cities lie on wide continental shelves, meaning deep water is far offshore,' Hilal says. Coastlines with steep drop-offs are ideal because shallow shelves would require long pipelines, adding to capital and operational costs. Fuglesang isn't worried about technical or engineering hurdles; he says the industry's biggest challenge will be aligning customers, governments and financial partners. Flocean is working on what will be the world's first large-scale subsea desalination plant, off the coast of Norway, and has a contract to start supplying water to an industrial facility in 2026. Netherlands-based Waterise has also secured its first industrial customer, with plans to start building a plant in the Red Sea's Gulf of Aqaba later this year, and Bay Area–based OceanWell is testing its prototype near Los Angeles. Long-term government contracts will most likely be needed for subsea desalination to really take off, and they may prove elusive. 'The water-infrastructure industry is quite conservative,' Fuglesang says, noting that because new projects are so expensive, 'nobody wants to be first' to go all-in on a new technology. Hilal says he believes subsea desalination could go mainstream and supply water to entire cities. But, he adds, 'reaching true city-scale will take time, conceivably a decade or more.'
Boston Globe
9 hours ago
- Boston Globe
Gates Foundation money fills gap in women's health
McKinsey Advertisement That's why the Gates Foundation's announcement of $2.5 billion in investments through 2030 for women's health — Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up The investment will fund research and development in maternal and obstetrical care to make pregnancy and childbirth safer, gynecological care and menstrual health, contraception, nutrition, and treatment of sexually transmitted infections. The Gates Foundation has a history of investing in areas that don't draw market-based or government funding. Its goal is to turn basic scientific research into cost-effective products that can be sold worldwide, particularly in lower-income countries. For example, at the STAT event, foundation founder Bill Gates showed off a plastic drape attached to a container with measuring marks that can be placed on the table where a woman is giving birth and used to measure blood loss. Postpartum hemorrhage can kill birthing women, and Gates said the $1 item can help health care providers identify dangerous blood loss, so treatment can be given sooner. Advertisement On the other end of the technological spectrum, Gates highlighted an artificial intelligence-powered ultrasound, currently being tested by Philips, that can send information to a health worker's cellphone about whether a pregnancy is high-risk. The goal is to make it easier for midwives in areas without ultrasound technicians to take an ultrasound, interpret the results, and send women with high-risk pregnancies for more advanced care. The good news for Massachusetts is the state's strong biotech ecosystem means some ideas funded by the Gates Foundation will be researched and developed here. For example, Giovanni Traverso, director of the Laboratory for Translational Engineering at MIT, received money to develop a transdermal patch that could provide women with long-term contraception. The lab is also developing probiotic medications to treat abnormalities in the vaginal microbiome, a condition associated with risks including painful infection and premature birth. Traverso said the foundation invests in high-risk, early-stage research that few commercial investors will back, then focuses on developing cost-effective products. 'The foundation again and again has been willing to take risks recognizing many things we do don't work. But if a few do, they could have a big impact,' Traverso said. Scott Johnson, CEO of Concord-based Comanche Biopharma, is trying to develop the first drug to treat preeclampsia (high blood pressure during pregnancy). If the drug is approved, Johnson said the Gates Foundation will help distribute it in low-income countries. The foundation gave Comanche Biopharma money to improve the chemical manufacturing process and package the drug in a prefilled syringe, making it cheaper and simpler to deliver. Advertisement Johnson hopes after initial trials in wealthier countries, Gates Foundation funding and expertise will help the company do clinical trials in Ghana, Kenya, and South Africa, with an eye toward getting the drug approved and distributed in areas where sales wouldn't otherwise be economically viable. Other Massachusetts grantees include researchers at Beth Israel Lahey Health, Mass General Brigham, Boston Children's Hospital, Harvard University, Fenway Health, Tufts University, and UMass Chan Medical School. Rasa Izadnegahdar, director of maternal, newborn, child nutrition and health for the Gates Foundation, said the goal is to catalyze private-sector investment in an area of health research with global applicability that has never had sustained funding. 'It's a high return-on-investment area,' Izadnegahdar said. 'That could be economic, societal, or from the lens of survival, including in low- and middle-income country settings. When you invest in improving the life of a woman, you're substantially increasing the opportunity of survival for her children, and it has an impact on the community.' Especially as the federal government cuts support for scientific research, Gates's investment highlights the good that can be done by private philanthropy filling the gap. Editorials represent the views of the Boston Globe Editorial Board. Follow us
Yahoo
a day ago
- Yahoo
At-home skin cancer test could be one step closer
The Brief An experimental patch could bring the medical world one step closer to rapid at-home melanoma testing, eliminating the need for a biopsy or blood draw. The ExoPatch successfully distinguished melanoma from healthy skin in mice, using a test that's similar to taking a COVID-19 test at home. Researchers believe the ExoPatch could be modified, potentially helping to detect other forms of cancer, including lung, breast, colon, prostate and brain cancer. Testing for the most aggressive form of skin cancer could one day be akin to taking a COVID-19 test at home, according to researchers at the University of Michigan. The researchers have developed a silicone patch – the ExoPatch – to distinguish melanoma from healthy skin. The patch worked when tested on mice. What this means Big picture view The ExoPatch could bring the medical world one step closer to rapid at-home melanoma testing, eliminating the need for a biopsy or blood draw, researchers said. What they're saying "The star-shaped needles make puncture easier and less painful, but they are so small that they only go through the top-most layer of the skin, the epidermis, and do not draw blood," said Sunitha Nagrath, a professor of Chemical Engineering at the university and co-corresponding author of the study published in Biosensors and Bioelectronics. "A fair-skinned person with moles must go to the doctor about every six months to send off a biopsy to see if they're malignant or benign. With this test, they could instead test at home, get the results right away and follow up with a dermatologist for a positive result," Nagrath said. How it works By the numbers The ExoPatch microneedles are 0.6 mm long with a width of less than 100 nanometers (0.0001 mm) at the tip. They're coated with a gel that picks up exosomes — or "tiny packages released by cells" — from the interstitial fluid that fills the spaces between cells in the epidermis. READ MORE: Rare flu complication causing brain swelling on the rise in kids, study finds Dig deeper Exosomes contain DNA and RNA fragments that cells use to communicate with each other. Exosomes help tumors spread, and detecting them can catch cancer sooner than other methods of detection, researchers found. The researchers first tested the ExoPatch on a tissue sample of pig skin, which closely resembles human skin in thickness and composition. The team also tested tissue samples of mouse skin, half from healthy mice and half from mice injected with a fragment of a human melanoma tumor. Once researchers confirmed that the exosomes stuck to the ExoPatch, they dissolved the gel and ran the sample through the test strips. READ MORE: What is Legionnaires' disease? Symptoms, how you get it "The test successfully distinguished between melanoma and healthy tissues with a 3.5-fold darker line in melanoma samples," researchers said. What's next Researchers are planning a pilot study in humans, followed by a series of clinical trials. They believe the ExoPatch could be modified, potentially helping to detect other forms of cancer, including lung, breast, colon, prostate and brain cancer. "The potential applications are huge," Nagrath said. The Source This report includes information from the University of Michigan. Solve the daily Crossword
